Palisade Bio (PALI) Notes Payables (2010 - 2013)

Palisade Bio (PALI) posted quarterly Notes Payables of $1.4 million for Q4 2013, up 8.05% quarter-over-quarter from $1.3 million in Q3 2013.

Palisade Bio (PALI) Notes Payables (2010 - 2013) Analysis & Trends

Palisade Bio (PALI) has reported Notes Payables for 2 consecutive years, with $1.4 million the latest figure, recorded in Q4 2013.

In Q4 2013, Notes Payables changed N/A year-over-year to $1.4 million; the TTM figure through Dec 2013 stood at $1.4 million (changed N/A YoY), while the FY2013 annual figure was $1.4 million, changed N/A from the prior year.
Notes Payables grew to $1.4 million in Q4 2013 per PALI's latest filing, from $1.3 million in the prior quarter.
Across five years, Notes Payables topped out at $1.4 million in Q4 2013 and bottomed at $445680.0 in Q1 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Palisade Bio	372.94 Mn	247.74 Mn	-

Download Data